A Phase Ib Study of the Oral PARP Inhibitor Olaparib With the Oral mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial, Triple Negative Breast, and Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 03 Sep 2019
Price : $35 *
At a glance
- Drugs Capivasertib (Primary) ; Vistusertib (Primary) ; Olaparib
- Indications Adenocarcinoma; Advanced breast cancer; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 23 Aug 2019 Planned End Date changed from 1 Nov 2021 to 30 Nov 2021.
- 23 Aug 2019 Planned primary completion date changed from 1 Nov 2020 to 30 Nov 2020.
- 31 Aug 2018 Biomarkers information updated